Stock XBRANE XBRANE BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
0.234 SEK +5.88% Intraday chart for Xbrane Biopharma AB -13.33% -97.66%
May. 22 Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? CI
May. 16 Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate
AQ
Xbrane Biopharma : successfully scales up Xdivane™ biosimilar candidate to Opdivo® and run an active partnering process
PU
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® - and run an active partnering process
AQ
Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?
CI
Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year
AQ
Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024
Xbrane Biopharma releases Interim Report for January-March 2024
AQ
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Xbrane Biopharma AB - Special Call
Xbrane Biopharma : Invitation to presentation of Xbrane Biopharma's interim report January - March 2024 on May 16, 2024
PU
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024
AQ
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar
MT
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
AQ
Announcement from Xbrane Biopharma's annual general meeting
AQ
Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director
CI
Transcript : Xbrane Biopharma AB - Special Call
Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate
AQ
Notice of annual general meeting in Xbrane Biopharma AB
AQ
Change of number of shares and votes in Xbrane
AQ
XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XBRANE Stock
  4. News Xbrane Biopharma AB